Archive for the ‘diabetes’ Category
2013 probably felt like it was going to be a great year for stem cell biologist Douglas Melton at Harvard. He had published a buzz-worthy paper in Cell about a new way to potentially boost insulin in diabetics, attracting significant media attention, and eventually gathering nearly 200 citations.
But 2016 is closing out on a less positive tone for Melton — today, he and his colleagues are retracting the paper, after multiple labs (including his own) couldn’t reproduce the findings.
Although the lab has itself already published two articles casting doubt on the original findings, Melton told Retraction Watch he chose to retract the paper to ensure there was no confusion about the original paper’s validity: Read the rest of this entry »
A researcher in Brazil is taking responsibility for accidentally mixing up images in three papers in the Journal of Biological Chemistry.
The corresponding author on the three papers told us the mistake happened because the studies were conducted simultaneously, and relied on one computer.
There’s a side note to these retractions: The co-author list on two papers includes names that should be fairly well-known to our readers — Mario Saad, the researcher who unsuccessfully sued the American Diabetes Association to stop retractions of his papers, and Rui Curi, a researcher whose legal threats assisted in the shutdown of Science-Fraud.org. This makes Saad’s ninth retraction.
According to the retraction notices, Lício Velloso — who, like his co-authors, is based at the University of Campinas in São Paulo, Brazil — assembled all the figures. He told Retraction Watch that the authors initially wanted to correct the papers, adding: Read the rest of this entry »
A researcher who received a lifetime funding ban for misconduct from a Canadian agency has logged her third retraction, after a re-analysis of her work unveiled “serious inconsistencies.”
In July, the Canadian Institutes of Health Research (CIHR) released a report about Sophie Jamal, following an investigation by her former employer, The Women’s College Hospital in Toronto, Canada. The probe concluded that Jamal had manipulated data, which resulted in her being banned from CIHR funding for life, and the retraction of a study in The Journal of the American Medical Association.
After that retraction, researchers that made up the the Canadian Multicentre Osteoporosis Study Group (CaMos) decided to take a second look at Jamal’s work. In August, we reported on a retraction that came out of that examination, in the American Journal of Kidney Diseases (AJKD). At the time, a senior researcher from the group told us the group had also requested another journal retract a CaMos paper.
The German Research Foundation (DFG) has announced today that it is withdrawing a professorship it awarded leading diabetes researcher Kathrin Maedler in 2014.
In recent years, Maedler — based at the University of Bremen in Germany — has faced questions about her work, including allegations of duplication and image manipulation. So far, she has issued one retraction, two expressions of concern, and multiple corrections. After an investigation, the University of Bremen concluded last month that Maedler’s work contained several duplications that were the result of negligence, noting there is not enough evidence to support charges of scientific misconduct.
But this hasn’t stopped the DFG from revoking the prestigious Heisenberg professorship it awarded Maedler in 2014. A Google-translated version of statement released by the DFG (in German) today concludes that Maedler did, in fact, commit misconduct, as she
Two papers evaluating glucose meters — used by diabetics to monitor blood sugar levels — suggested that a couple of the devices don’t work as well as they should. Perhaps unsurprisingly, the companies that sell those meters objected to how the studies were conducted. By all accounts, the companies appear to be justified in their complaints.
In both cases, researchers used blood drawn from veins to test the meters. But manufacturers of the WaveSense JAZZ and GlucoRx glucose meters said their devices are designed to work with fresh blood from a finger-prick. Both papers have now been retracted.
The retraction notice for “Technical and clinical accuracy of five blood glucose meters: clinical impact assessment using error grid analysis and insulin sliding scales,” published in 2015 in the Journal of Clinical Pathology, hints at the issue:
A biologist at the University of Georgia has lost a paper after an investigation revealed she had tampered with three images.
In 2014, Azza El-Remessy notched three retractions for a series of image errors. Now, a fourth retraction notice, and an expression of concern, explain there has been an investigation into her work. The investigation — conducted by two Georgia institutions, along with the Charlie Norwood Veterans Affairs Medical Center, where El-Remessy has additional appointments — has found evidence of misconduct.
Several duplications in the work of a prominent diabetes researcher were the result of negligence, but there is not enough evidence to support charges of misconduct, according to an investigation at her university in Germany.
Recently, we’ve reported on several notices for papers co-authored by Kathrin Maedler, a researcher at the University of Bremen. So far, Maedler has one retraction, multiple corrections, and two expressions of concern to her name, after several of her papers were questioned on PubPeer. Previously, the University of Zurich in Switzerland — where Maedler completed her PhD in 2002 — determined there was a lack of evidence to support allegations of misconduct in papers that were part of her doctoral thesis.
According to the retraction notice, the first and corresponding author — Eric Berglund, formerly at Vanderbilt University in Nashville, Tennessee — contacted the journal himself to report the error, for which he takes full responsibility.
All three papers share a number of authors, including the same last and corresponding author, Aimin Xu, from The University of Hong Kong.
Since the corrections appear relatively extensive, we asked the journal if retractions were ever on the table. According to Chris Kohler, associate publisher, scholarly journals at American Diabetes Association, which publishes Diabetes, an ethical panel reviewed the papers before allowing the authors to issue the errata, all of which were published online this month: Read the rest of this entry »
We previously reported on the case after the VTT was accused of cutting corners in a previous investigation into Matej Orešič (now based at the Steno Diabetes Center in Gentofte, Denmark). In 2014, the VTT concluded that there was no evidence of falsification or data tampering on the part of Orešič in the 2008 paper published in the Journal of Experimental Medicine (JEM). The proceedings came into the public domain through a news article published in the Finnish media outlet Helsingin Sanomat in February 2016, which prompted the VTT to reopen the case.
Now, the same people who questioned the previous investigation told us they have doubts about the latest conclusions, noting the probe should not have focused on a single paper, but rather on alleged problems within the plasma and serum metabolomics group, previously led by Orešič.